REFERENCES
1. Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027-50.
2. Janić M, Janež A, El-Tanani M, Rizzo M. Obesity: recent advances and future perspectives. Biomedicines. 2025;13:368.
3. Xu Y, Jia W, Niu X, et al. Prevalence and comorbidity network analysis of obesity and related complications: a real-world study based on 233,004 individuals. Diabetes Metab Syndr Obes. 2025;18:3297-314.
5. Kivimäki M, Strandberg T, Pentti J, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10:253-63.
6. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27:66-88.
7. Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021;23:404-14.
8. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
9. Luo J, Xiang Q, Lin T, et al. Associations between total and regional fat-to-muscle mass ratio and osteoarthritis incidence: a prospective cohort study. Osteoarthritis Cartilage. 2025;33:1023-32.
10. Benz E, Pinel A, Guillet C, et al. Sarcopenia and sarcopenic obesity and mortality among older people. JAMA Netw Open. 2024;7:e243604.
11. Liu Z, Huang Q, Deng B, et al. Elevated Chinese visceral adiposity index increases the risk of stroke in Chinese patients with metabolic syndrome. Front Endocrinol. 2023;14:1218905.
12. Zhang Z, Zhao L, Lu Y, Meng X, Zhou X. Association between Chinese visceral adiposity index and risk of stroke incidence in middle-aged and elderly Chinese population: evidence from a large national cohort study. J Transl Med. 2023;21:518.
13. Neeland IJ, Ross R, Després JP, et al.; International Atherosclerosis Society, International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7:715-25.
14. Mina T, Yew YW, Ng HK, et al. Adiposity impacts cognitive function in Asian populations: an epidemiological and Mendelian Randomization study. Lancet Reg Health West Pac. 2023;33:100710.
15. Raji CA, Meysami S, Hashemi S, et al. Visceral and subcutaneous abdominal fat predict brain volume loss at midlife in 10,001 individuals. Aging Dis. 2024;15:1831-42.
16. Losev V, Lu C, Tahasildar S, et al. Sex-specific body fat distribution predicts cardiovascular ageing. Eur Heart J. 2025;46:5076-88.
17. Jayedi A, Soltani S, Zargar MS, Khan TA, Shab-Bidar S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ. 2020;370:m3324.
18. Guo J, Wei Y, Heiland EG, Marseglia A. Differential impacts of fat and muscle mass on cardiovascular and non-cardiovascular mortality in individuals with type 2 diabetes. J Cachexia Sarcopenia Muscle. 2024;15:1930-41.
19. Chen S, Wang X, Jin Y, et al. Assessment of changes in body composition after 3 months of dulaglutide treatment. Diabetes Metab Syndr Obes. 2024;17:1301-8.
20. McCrimmon RJ, Catarig AM, Frias JP, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473-85.
21. Uchiyama S, Sada Y, Mihara S, Sasaki Y, Sone M, Tanaka Y. Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes. J Clin Med Res. 2023;15:377-83.
22. Alissou M, Demangeat T, Folope V, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2026;28:112-21.
23. Bu T, Sun Z, Pan Y, Deng X, Yuan G. Glucagon-like peptide-1: new regulator in lipid metabolism. Diabetes Metab J. 2024;48:354-72.
24. Hropot T, Herman R, Janez A, Lezaic L, Jensterle M. Brown adipose tissue: a new potential target for glucagon-like peptide 1 receptor agonists in the treatment of obesity. Int J Mol Sci. 2023;24:8592.
25. Martins FF, Marinho TS, Cardoso LEM, et al. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct. 2022;40:903-13.
26. Papakonstantinou I, Tsioufis K, Katsi V. Spotlight on the mechanism of action of semaglutide. Curr Issues Mol Biol. 2024;46:14514-41.
27. Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024;11:1398059.
28. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367.
29. Xiang J, Qin L, Zhong J, Xia N, Liang Y. GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes. 2023;16:2433-46.
30. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.
